February 2025

Bimekizumab improves patient-reported outcomes and work productivity in patients with psoriatic arthritis: 1-Year results from two Phase 3 studies

J Rheumatol 2025. Epub ahead of print doi: 10.3899/jrheum.2024-0923

Gladman et al. assessed the impact of bimekizumab over 1 year on patient-reported symptoms, HRQoL, and work productivity in patients with PsA who were bDMARD-naïve or TNF-IR. The study showed that bimekizumab treatment resulted in sustained improvements across multiple domains, including pain, fatigue, physical function, and work impairment.

Keywords:

June 2024

Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-Year results from two Phase 3 studies

Journal Reference: Rheumatology 2024 Epub ahead of print doi: 10.1093/rheumatology/keae277

Compared with placebo, bimekizumab-treated patients displayed a rapid clinically meaningful improvement in PsAID-12 scores at Week 4, which continued to Week 16 and was sustained to 1 year. Gossec et al. assessed 1-year bimekizumab efficacy from the patient perspective using the PsAID-12 questionnaire in bDMARD-naïve (BE OPTIMAL) and TNFi-IR (BE COMPLETE) patients with active PsA.

Keywords:

April 2024

Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two Phase 3 randomized trials in plaque psoriasis

Am Acad Dermatol 2023. doi: 10.1016/j.jaad.2023.11.060

This pooled analysis of the Phase 3 PSO-1 and PSO-2 trials shows that deucravacitinib has greater efficacy in treating scalp PsO than placebo and apremilast. At week 16, response rates were greater with deucravacitinib versus placebo or apremilast for scalp-specific Physician Global Assessment 0/1 and Psoriasis Scalp Severity Index. Efficacy was maintained through 52 weeks in patients who received continuous deucravacitinib treatment.

Keywords:

February 2024

Validity and Score Interpretation of the 12-item Psoriatic Arthritis Impact of Disease: An Analysis of Pooled Data from Two Phase 3 Trials of Bimekizumab in Patients with Psoriatic Arthritis

RMD Open 2024;10(1):e003548 doi: 10.1136/rmdopen-2023-003548

This study reports that the PsAID-12 total score and individual PsAID items capturing disease concepts important to patients with PsA demonstrated robust psychometric properties.

Keywords: